Vascular risk factor control and adherence to secondary preventive medication after ischaemic stroke.

BACKGROUND: Studies regarding adequacy of secondary stroke prevention are limited. We report medication adherence, risk factor control and factors influencing vascular risk profile following ischaemic stroke. METHODS: A total of 664 home-dwelling participants in the Norwegian Cognitive Impairment After Stroke study, a multicenter observational study, were evaluated 3 and 18 months poststroke. We assessed medication adherence by self-reporting (4-item Morisky Medication Adherence Scale) and medication persistence (defined as continuation of medication(s) prescribed at discharge), achievement of guideline-defined targets of blood pressure (BP) (<140/90 mmHg), low-density lipoprotein cholesterol (LDL-C) (<2.0 mmol L-1 ) and haemoglobin A1c (HbA1c) (≤53 mmol mol-1 ) and determinants of risk factor control. RESULTS: At discharge, 97% were prescribed antithrombotics, 88% lipid-lowering drugs, 68% antihypertensives and 12% antidiabetic drugs. Persistence of users declined to 99%, 88%, 93% and 95%, respectively, at 18 months. After 3 and 18 months, 80% and 73% reported high adherence. After 3 and 18 months, 40.7% and 47.0% gained BP control, 48.4% and 44.6% achieved LDL-C control, and 69.2% and 69.5% of diabetic patients achieved HbA1c control. Advanced age was associated with increased LDL-C control (OR 1.03, 95% CI 1.01 to 1.06) and reduced BP control (OR 0.98, 0.96 to 0.99). Women had poorer LDL-C control (OR 0.60, 0.37 to 0.98). Polypharmacy was associated with increased LDL-C control (OR 1.29, 1.18 to 1.41) and reduced HbA1c control (OR 0.76, 0.60 to 0.98). CONCLUSION: Risk factor control is suboptimal despite high medication persistence and adherence. Improved understanding of this complex clinical setting is needed for optimization of secondary preventive strategies.

Increasing mortality from amyotrophic lateral sclerosis in Norway?

OBJECTIVE: To investigate a possible increase in incidence of ALS in Norway. METHODS: Death certificate data from all deaths in Norway in the period 1961 to 1994 for ALS, PD, and MG were obtained from Statistics Norway and related to population statistics. Data on ALS was obtained on sex, age, and place of death and compared with mortality data in PD and MG for the same period. Data were standardized using the 1990 population as standard population. Poisson regression was used to test for trends in mortality. The data from the death certificates were related to a clinical study performed on ALS in one of the counties during the same period. RESULTS: The annual mortality of ALS almost doubled during the period studied, rising from 1.38 to 2.54 per 100,000 inhabitants at the end of the study. The increased mortality appeared solely in the population older than 60 years of age, with a peak in mortality in the age group 80 to 84 years. The increase was larger in women than in men, and the ratio between the sexes was 1.32 (men-women, age-adjusted at the end of the study). The mortality in patients with PD showed a similar increase to that seen in ALS, whereas no increase in mortality was observed in patients with a diagnosis of MG. There were considerable differences in ALS mortality in different counties, but no clear regional trends were observed. CONCLUSION: The authors report increasing ALS mortality. Although the increase in mortality is restricted to the population aged 65 years or older, it cannot be explained by increasing age of the general population alone.